Press Releases

Date Title and Summary Additional Formats
Toggle Summary Once-daily Trelegy Ellipta gains expanded COPD indication in Europe
First single inhaler triple therapy to be specifically indicated for COPD patients not adequately treated with dual bronchodilation LONDON --(BUSINESS WIRE)--Nov. 9, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has
View HTML
Toggle Summary Innoviva Reports Third Quarter 2018 Financial Results
Total net revenue rose 26.8% to $61.7 million compared with the third quarter of 2017. Net income attributable to Innoviva stockholders increased 98.1% from the third quarter of 2017 to $47.1 million , or $0.43 per diluted share. The Company made a partial repayment of $110.0 million on its Term B
View HTML
Toggle Summary Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded COPD Indication in Europe
LONDON --(BUSINESS WIRE)--Sep. 21, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta
View HTML
Toggle Summary Innoviva Reports Second Quarter 2018 Financial Results
Total net revenue rose 14.6% to $67.1 million compared with the second quarter of 2017. Net income attributable to Innoviva stockholders increased 55.4% from the second quarter of 2017 to $54.6 million , or $0.49 per diluted share. The Company intends to prepay $110 million of its Term B Loan.
View HTML
Toggle Summary Innoviva Names Geoffrey Hulme as Interim Principal Executive Officer
Hulme to execute capital allocation review and cost cutting initiatives of the board; will also oversee investigation into conduct of advisors to the board in connection with 2017 proxy contest BRISBANE, Calif. --(BUSINESS WIRE)--May 22, 2018-- Innoviva, Inc.
View HTML
Toggle Summary Innoviva Reports First Quarter 2018 Financial Results
Royalties earned rose 28% to $55.8 million compared with the first quarter of 2017. Net income attributable to Innoviva stockholders increased 76% from the first quarter of 2017 to $29.6 million , or $0.29 per basic share. BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 26, 2018-- Innoviva, Inc.
View HTML
Toggle Summary Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPD
LONDON & BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 24, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration ( FDA ) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol
View HTML
Toggle Summary Landmark IMPACT Study Published in NEJM Shows Significant Benefits of Trelegy Ellipta for Patients with COPD
Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across multiple endpoints including exacerbations, lung function and quality of life LONDON & BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 18, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc.
View HTML
Toggle Summary GSK Announces Positive EU Approval for Labelling Update to Relvar Ellipta in Patients with Asthma
LONDON & BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 8, 2018-- GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled
View HTML
Toggle Summary GSK Submits Landmark IMPACT Data to European Medicines Agency to Support Expanded Label for Trelegy Ellipta
LONDON & BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 14, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy
View HTML

Copyright West LLC. Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.